Tetra Bio-Pharma has submitted multiple orphan drug applications to the FDA for cannabinoid treatment of rare cancers and ocular diseases, the company announced in a release.
An orphan drug designation would allow for fast track approvals, tax credits on clinical research and reduced registration fees, the release said.
“Managing rare forms of cancer presents a huge challenge for physicians,” Tetra Bio-Pharma interim CEO and chief scientific officer Guy Chamberland, MSc, PhD, said. “Our R&D team has submitted numerous orphan drug designation applications to the FDA over
Uncategorized